JJ
ACET icon

Johnson & Johnson’s Adicet Bio ACET Stock Holding History

Johnson & Johnson’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$155K Hold
22,779
– – 0.02% 16
2025
Q4 		$192K Sell
22,779
-1
-0% -$11 0.03% 17
2025
Q3 		$295K Hold
22,780
– – 0.06% 18
2025
Q2 		$228K Hold
22,780
– – 0.07% 18
2025
Q1 		$275K Hold
22,780
– – 0.08% 18
2024
Q4 		$351K Hold
22,780
– – 0.09% 18
2024
Q3 		$525K Hold
22,780
– – 0.12% 17
2024
Q2 		$441K Hold
22,780
– – 0.11% 19
2024
Q1 		$857K Sell
22,780
-20,257
-47% -$838K 0.02% 18
2023
Q4 		$1.3M Sell
43,037
-2,522
-6% -$55K 0.03% 16
2023
Q3 		$999K Hold
45,559
– – 0.37% 17
2023
Q2 		$1.77M Hold
45,559
– – 0.55% 15
2023
Q1 		$4.2M Hold
45,559
– – 1.37% 13
2022
Q4 		$6.52M Hold
45,559
– – 1.9% 13
2022
Q3 		$10.4M Hold
45,559
– – 3.05% 10
2022
Q2 		$10.6M Hold
45,559
– – 2.72% 10
2022
Q1 		$14.6M Hold
45,559
– – 2.75% 11
2021
Q4 		$12.7M Hold
45,559
– – 1.45% 11
2021
Q3 		$5.71M Buy
+45,559
New +$5.65M 0.5% 14

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Johnson & Johnson's ACET Position: Q1 2026 in Review

Johnson & Johnson held its Adicet Bio (ACET) position steady in Q1 2026 at 22,779 shares worth $155K. The position accounts for 0.02% of the portfolio, ranked #16.

Johnson & Johnson first reported a position in ACET in Q3 2021 and has held it in 19 quarters since. The position peaked at $14.6M in Q1 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Johnson & Johnson held 22,779 shares of Adicet Bio worth $155K as of Q1 2026.
  • Johnson & Johnson left its Adicet Bio share count unchanged in Q1 2026.
  • Adicet Bio made up 0.02% of Johnson & Johnson's portfolio in Q1 2026, its #16 holding.
  • Johnson & Johnson first reported a position in Adicet Bio in Q3 2021 and has held it in 19 quarters since.
  • Johnson & Johnson's Adicet Bio position peaked at $14.6M in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Johnson & Johnson's 13F filing for Q1 2026, filed 13 May 2026.